Pentosan polysulfate sodium is under clinical development by Paradigm Biopharmaceuticals and currently in Phase II for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ). According to GlobalData, Phase II drugs for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Pentosan polysulfate sodium LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pentosan polysulfate sodium overview

Pentosan polysulfate sodium (PPS) is under development for the treatment of osteoarthritis of the knee, osteoarthritis pain, mucopolysaccharidosis I (MPS I), MPS VI, bone marrow edema, heart failure, allergic asthma, seasonal allergic rhinitis, RRV (Ross River virus), coronavirus disease 2019 (COVID-19) associated acute respiratory distress syndrome and CHIKV (chikungunya virus) induced arthritis and arthralgia (joint pain). It is administered by subcutaneous, intramuscular route and intra-nasal route. It is a semi synthetic polysaccharide developed based on repurposing strategy. It acts by targeting ADAMTS-5, Collagenase 3 and Stromelysin-1.

Paradigm Biopharmaceuticals overview

Paradigm Biopharmaceuticals (Paradigm Biopharma), is a biopharmaceutical company. The company is engaged in the research and development of therapeutic products for human usage. It offers pentosan polysulfate sodium (PPS) drugs for new orthopedic and respiratory applications. Paradigm Biopharma offers drugs in both injectable and tablet forms for bone marrow edema, respiratory disease, alphaviral arthritis, orthopedic, alphavirus, and respiratory diseases. The company’s other activities include treating the allergic inflammatory response in allergic rhinitis (AR). It also conducts a phase 2b clinical trial to investigate PPS in subjects with Bone Marrow Lesions (BMLs) and osteoarthritis (OA). Paradigm Biopharma is headquartered in Melbourne, Victoria, Australia.

For a complete picture of Pentosan polysulfate sodium’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.